low-dos lumateperon disappoint agit
intra-cellular announc dmc recommend stop trial
low-dos lumateperon treatment agit
alzheim base futil studi assess low dose
compani state gener well toler pharmacolog becom
broader dose increas low dose may play role
lack activ set remain posit dose
fda review treatment schizophrenia note bipolar
depress monotherapi studi employ dose remov
agit alzheim model lower pt
differenti profil open label schizophrenia studi patient
switch achiev weight loss month also
show favor cardiometabol endocrin safeti notabl also
improv efficaci base panss score favor
safeti profil pair solid efficaci believ support
differenti profil potenti broad-bas use schizophrenia
prep schizophrenia approv pre-commerci
activ progress potenti use schizophrenia
compani hire chief commerci offic along key medic
regulatori personnel believ rel benign advers event
believ blockbust potenti schizophrenia possibl
indic well multi-billion-dollar peak sale potenti
addit molecul also emerg novel
inhibitor demonstr clinic sign suggest reduct motor
symptom complic parkinson patient increas on-
time without caus dyskinesia move parkinson
clinic heart failur also shown promis activ
novel serotonin dopamin mu opiat receptor modul
also consider substanc abus depress pain
valuat today announc npv estim
exhibit price target move
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
exhibit propos metabol pathway human
 davi correl treatment schizophrenia novel pharmacolog clinic outcom expert review
exhibit receptor bind profil metabolit human
 davi correl treatment schizophrenia novel pharmacolog clinic outcom expert review
intra-cellular therapi cns-focus intra-cellular therapi new
york-bas biopharmaceut compani focu discoveri
develop small molecul drug address underserv need
neuropsychiatr neurolog disord found base
technolog intra-cellular co-found nobel laureat dr paul greengard
compani detail understand intracellular signal pathway
target believ help better inform select develop
candid manag team signific industri experi
complement scientif clinic advisor schizophrenia
sever larg indic intra-cellular lead product candid
lumateperon complet sever larg clinic trial schizophrenia
phase studi bipolar depress behavior disturb
dementia/alzheim diseas novel pharmacolog
potenti effect across wide rang schizophrenia symptom
improv safeti toler compar atyp antipsychot iti-
also differ pharmacodynam activ across rang dose
provid potenti activ across broad rang
disord includ major depress disord addit alreadi
examin late stage clinic work exhibit versatil potenti
multipl larg indic form basi estim
 antagon dose sleep benefit
 dopamin occup minim dose increas w/dose
 minim activ metabol ae-rel receptor
 multipl indic schizophrenia agit alzheimers/dementia
bipolar disord depress parkinson psychosi
also develop pde inhibitor multipl indic intra-cellular
addit program focus cognit impair associ
schizophrenia alzheim diseas effort yield compound
select inhibit phosphodiesteras pde lead program
focus earli clinic studi disord
parkinson diseas other consider model parkinson
diseas inhibitor improv motor symptom enhanc dopamin
signal stand-alon treatment earli parkinson may possibl iti-
suffici endogen dopamin avail support synapt
activ also could l-dopa da agonist spare diseas
progress potenti prolong da replac strategi reduc
advers event also consider heart failur
preclin data demonstr benefici effect cardiac function
inhibit increas cardiac contractil output
antipsychot characterist lumateperon activ key mediat
antipsychot efficaci antagonist receptor
antagonist activ dopamin receptor yet differenti
behavior receptor potent receptor antagonist
low dose confer antipsychot potenti addit molecul
show low dopamin receptor occup low dose receptor
occup increas dose increas exhibit dopamin
receptor distinguish pre-synapt partial agonist
post-synapt antagonist activ brain region-specif manner
collect thought provid increment antipsychot efficaci
limit motor disturb seen therapi
thought benefici impact multipl symptom domain schizophrenia
affect system believ caus undesir side effect
cognit dysfunct cardio-metabol abnorm
exhibit dial dopamin receptor activ
davi correl treatment schizophrenia novel pharmacolog clinic
outcom expert review
notabl activ sert serotonin transport
receptor sert engag result serotonin reuptak inhibit higher
dose demonstr antidepress activ human
glutam receptor phosphoprotein modul molecul
thought enhanc glutam transmiss result dopamin
agonist activ confer potenti neg symptom control
schizophrenia cognit enhanc pro-soci behavior
appear antagonist activ muscarin receptor
minim metabol cardiovascular advers event seen newer
atyp antipsychot collect broad pharmacolog profil
predict result clinic meaning antipsychot efficaci
posit neg symptom schizophrenia also aid improv
mood social integr prosoci activ moder advers
event lumateperon familiar yet uniqu profil potenti
accord dr jeffrey lieberman speak american psychiatr
associ meet next meaning therapeut horizon
dosag molecul also potenti treatment
bipolar disord major depress disord neuropsychiatr diseas
exhibit given activ relat follow-on compound
intra-cellular alreadi examin molecul late stage studi
indic bipolar depress agitation/aggress dementia
includ alzheim given rel benign advers event profil
like consid major depress disord psychosi associ
parkinson diseas among indic
exhibit signific efficaci initi phase schizophrenia total panss left psp
vanov et al posit phase clinic trial treatment schizophrenia secondari endpoint subgroup analys
data show efficaci rel clean ae profil
larg schizophrenia trial one phase one phase studi iti-
effect treat schizophrenia measur chang
baselin total panss score compar placebo phase
phase initi phase separ first week activ
exhibit left graph also show statist signific cgi-
scale anoth import efficaci measur phase studi also
demonstr prosoci activ exhibit right graph phase
show less neg affect compar risperidon mild somnol
materi advers event phase phase rate
importantli across larg studi demonstr littl
glucos insulin prolactin weight cholesterol elev movement
disturb ep akathisia dystonia seen atyp exhibit
chang right initi phase schizophrenia
sourc vanov et al posit phase clinic trial treatment schizophrenia secondari endpoint subgroup analys random
double-blind placebo-control trial poster sir annual meet vanov et al clinic develop treatment schizophrenia
despit success phase phase studi patient
patient respect patient schizophrenia second phase trial
slightli differ design week activ control
patient separ placebo measur total panss
primari endpoint type result happen occasion studi
studi placebo arm perform much better prior
studi perform roughli line previou work trial design
question center around function unblind due inclus
risperidon make obviou activ drug four-
arm/three-act design importantli trial other
continu differenti advers event profil differ
compar placebo akathisia movement disturb well
prolactin bodi weight glucos insulin lipid regard path
forward schizophrenia therapi approv least
two well-control studi show efficaci dose despit
studi demonstr efficaci believ compani choos file
nda schizophrenia without conduct addit efficaci work
howev point long-term safeti studi appear gate item
believ consider potenti schizophrenia beyond
despit recent phase hiccup may modestli dampen percept
around efficaci estim therapeut schizophrenia
differenti pharmacolog result rel benign advers event
profil could meaning util peak revenu eventu
approach billion global potenti bipolar depress major
lumateperon indicationstatusest approvalpeak estimate schizophreniaphas disord depress mania phase disturb depress disorderphas othersphas
roughli doubl schizophrenia addit activ elderli
dementia emerg pathway approv agitation/aggress
behavior disturb patient indic could add sever
addit billion dollar potenti though neg phase interim
look make behavior disturb revenu unlik collect
indic without dementia could exceed billion peak exhibit
metabolit molecul provid interest opportun line
extens includ long-act version current develop
potenti develop activ metabolit
receptor antagonist inhibitor serotonin reuptak
roughli equal potenc two target provid opportun
signific line extens depress mood disord believ intra-
cellular develop relat molecul mood disord
model separ though includ revenu long-act inject
part franchis
compani becam publicli trade entiti revers merger also
rais million privat placement continu develop
multipl indic primarili schizophrenia
demonstr posit phase result dose larg
patient studi acut schizophrenia potenti larg
initi indic demonstr posit overal efficaci
compar risperd even better measuresprosoci
element lack exacerb neg symptom molecul
dateeventcommentimportanceaug equiti privat placement revers mergerconvert note equiti revers merg public listingvvvdec larg phase studi show solid efficaci good tolerabilityvvvvvfeb intra-cellular progress schizophrenia bipolar disordervvvmay meet phase data differenti risperidon pk profil describedvvvvvmay meet phase data note next meaning therapeut horizon vvvvoct meet low-dos geriatricsdata show good toler dose meet low-dos data low-dos appear safe improv cognitionvvvvnov phase schizophrenia trial start week studi read posit discontinu clinic program return work continuesvvmar rais net schizophenia bipolar disordervvvjun phase schizophrenia studi start activ control studi risperidon read vvvsept occup data show select activ differenti profilevvvsept phase data schizophrenia positivesuccess major catalyst rais net earli commerci prep multipl add begin phase studi bipolar depressionind could provid materi add revenu begin agit wk trial result could materi valu driver vvvvsept phase schizophrenia negativeuncertainti file approv ae profil still look met w/fda discuss nda submissionefficaci ok safeti question push submiss advanc inhibitorind includ parkinson chf usesvvvoct rais net multipl add indic indic morevvvnov receiv fda track design schiz track grant unmet clinic need indicationvvvv import rate least import vvvvv import
show notabl lack metabol event movement disord cholesterol
prolactin elev compar risperd
jan intra-cellular rais million heel posit phase
data schizophrenia initi public offer compani rais
million million net though offer million share
order fund broader develop
oct show import phase result geriatr
dementia studi examin low dose
establish safeti toler elderli patient healthi
dementia molecul perform well enough advanc
potenti extrem larg indic behavior disturb
dementia also known alzheim agit part one studi show
safe effect low dose part two show signal
improv cognit healthi elderli patient elderli patient
dementia result led robust studi indic could
add multibillion-dollar potenti
million net though offer million share
order fund broader develop
sept initi phase result posit differenti
initi phase studi schizophrenia posit
primari endpoint total panss score well secondari
endpoint cgi- measur prosoci activ importantli safeti
toler profil also provid potenti approv
schizophrenia materi indic well
sept intra-cellular rais million heel initi
posit phase data schizophrenia compani rais million
million net though offer million share order
fund broader develop earli commerci prepar
advanc addit formul novel
inhibitor non- use
 begin phase trial bipolar depress activ
antipsychot activ sert serotonin receptor transport
compani chosen develop use bipolar depress bipolar
ii patient experienc major depress episod enrol
indic could materi add potenti
june pivot work begin behavior disturb
agitation/aggress dementia/alzheim potenti larg
indic recogn readili alzheim agit aid
previou data elderli show cognit activ good toler
low dose activ antipsychot benefici effect
sleep may also help play role use set
sept whiff second phase schizophrenia
separ placebo primari endpoint second phase studi
though excel toler profil reinforc trial
slightli differ prior phase studi longer
endpoint elucid advers event differ activ arm
risperidon includ trial overal panss reduct
studi similar previou trial placebo arm trial simpli
perform much better despit result intra-cellular gener
posit result two larg well-control studi
updat nda file strategi schizophrenia like
intra-cellular posit result two larg studi iti-
schizophrenia one phase one phase addit phase studi
show posit efficaci molecul base discuss
fda march manag state efficaci appear
enough file howev recent discuss regard safeti owe
preclin toxic seen dog appear human dog
metabol differ human result metabolit
anim detect human posit intra-cellular base
addit dialog intra-cellular file nda septemb
place potenti us approv schizophrenia
million million net order fund broader develop iti-
earli clinic studi novel inhibitor
parkinson indic begin initi stage
commerci activ lumateperon
intra-cellular gain track design lumateperon
schizophrenia track design lumateperon receiv base
clinic evid potenti address unmet medic need
treatment schizophrenia signific improv clinic
metabol motor
cardiovascular issu associ mani current avail antipsychot
track design facilit develop expedit review
drug candid treat seriou life-threaten condit may allow
frequent meet commun fda discuss drug
candid develop plan review process drug candid
track may also qualifi prioriti review expedit fda review process
schizophrenia
manag initi roll nda file schizophrenia june
complet file
septemb place potenti us approv
schizophrenia
nda potenti file schizophreniafil expect result regular review cycl interim phase data agit w/dimentiameaning efficaci could addit valu three phase bipolar depressionphas studi includ monotherapi licens global geographieslicens could non-dilut sourc capit us approv schizophreniaind seimin event intra-cellularvvvvv import rate least import vvvvv import
behavior disturb
interim pivot result
agitation/aggress dementia/alzheim phase trial
patient plan random receiv placebo
daili four week studi includ singl interim analysi
use assess assumpt variabl effect size primari
efficaci measur cohen-mansfield agit inventori commun
version cmai-c scale measur drug abil reduc
overal frequenc agit symptom includ aggress behavior
key secondari efficaci measur clinic global impress scale sever
cgi- ill exploratori secondari endpoint includ measur
behavior disturb associ dementia benefici effect
sleep may help play role set indic could ultim add
materi multibillion-dollar potenti molecul peak revenu given
molecul rel benign ae profil interim look determin
studi stop futil
initi phase result bipolar depress three-
arm studi examin versu placebo bipolar ii
patient monotherapi adjunct therapi combin
lithium valproat primari endpoint chang baselin
madr week addit help robust data
indic intra-cellular chosen conduct third studi
global phase monotherapi studi bipolar ii patient also primari
endpoint chang madr baselin week data readout
monotherapi trial expect compani attempt
ensur high-qual enrol posit result bipolar depress like
help materi differenti therapi studi posit file
indic expect approxim six month final result
announc model sometim late approv
indic
intra-cellular therapi valuat number signific event expect
come quarter year give intra-cellular potenti materi
earn variabl time employ sum-of-the-parts/net
present valu npv methodolog valu oper share price
appli risk weight individu asset case
sever larg indic assess opportun individu
consid program quit valuabl given materi unmet
need respect set gener reflect revenu
potenti figur rel valuat risk somewhat
mitig initi schizophrenia indic result phase
data show solid safeti toler activ schizophrenia patient
dose howev posit data off-set
preclin find molecul
intra-cellular oper independ assess total valu intra-
cellular program asset per share exhibit
adjust risk program across indic due toxic seen
anim studi calcul assum intra-cellular continu
oper independ approv schizophrenia anoth
success phase result believ potenti remain modest
assess intra-cellular total npv larg deriv valu
new drug pipelin princip potenti novel
antipsychot lumateperon consid multipl
indic initi indic schizophrenia posit phase data
unmet need set uniqu properti
advanc clinic stage indic valu indic
assign discount launch given
septemb pdufa indic bipolar depress
depress modestli higher risk yet given pharmacolog activ
believ reason potenti success quit larg
valuat follow neg interim analysi
phase program behavior disord dementia remov
program npv calcul prior npv
indic lesser potenti higher risk npv
behavior potenti depress along
asset intra-cellular pde pipelin result valu
estim nol credit less
corpor overhead unattributed/gener neg
yield total per share basic assumpt includ fully-
tax figur share count approxim million
versatil antipsychot multipl indic
lumateperon uniqu molecul design benefici impact multipl
symptom domain schizophrenia affect system thought
caus undesir side effect cognit dysfunct metabol
cardiovascular abnorm lumateperon activ key mediat
antipsychot efficaci dopamin phosphoprotein modul partial
intra-cellular asset bipolar disord behav dis/agg dementia parkinson metabolit asset credit asset asset
agonist/antagonist activ dopamin receptor yet
differenti behavior receptor also antagonist
low dose receptor importantli addit differenti
pharmacolog activ serotonin transport sert potenti
confer antidepress activ furthermor shown enhanc
glutamaterg transmiss brain area involv cognit function
provid potenti improv pro-soci activ molecul
collect believ differenti profil potenti wide
consid physician materi number larg ill
condit result multibillion-dollar potenti
kol note davi correl expert review
neurotherapeut recogn differenti potenti
refer current approv antipsychot associ
placebo-lik metabol profil well low propens caus epss
also note potenti wide-rang applic lumateperon
pharmacolog novel molecular entiti uniqu pharmacolog
properti suffici divers pharmacodynam effect differ
clinic differenti dose potenti use varieti
divers neuropsychiatr disord
activ receptor dose one import
characterist low dose present
antagon provid import activ receptor known possess core
antipsychot activ well benefit sleep initi studi low dose
human show activity/improv sleep mainten iti-
improv sleep mainten gener associ
receptor antagon activ confer antipsychot efficaci
lower dose may provid benefit patient agit
indic
exhibit vitro receptor bind compar commonli
target schizophrenia character vivo vitro anim
differenti dopamin receptor dial antagon
dose increas addit benefit deriv
engag addit target includ dopamin receptor modul
inhibit serotonin transport healthi volunt striatal
receptor occup rise increas
dose increas combin activ receptor
increas dose thought provid addit benefit antipsychot
efficaci beyond antagon treat multipl
indic schizophrenia bipolar disord
dopamin receptor behavior also predict lack motor
dopamin phosphoprotein modul dppm function act
pre-synapt partial agonist post-synapt antagonist dopamin
receptor vivo assay novel profil antipsychot exhibit
mechan also exhibit select increas dopamin
concentr medial prefront cortex consist atyp
predict antipsychot efficaci time also appear
preserv normal dopamin neurotransmiss striatum point toward
low liabil motor side effect molecul uniqu
dopaminerg receptor behavior creat potenti
rel low movement advers event liabil demonstr
advanc studi clinic could possibl even lead rel lack
emerg tardiv dyskinesia util
use depress dose increas engag
sert serotonin transport also begin transport remov
serotonin synapt cleft target ssri class
antidepress nm inhibitor transport increas
amount serotonin synaps engag sert begin
show antidepressant-lik effect initi clinic evid effect
demonstr phase schizophrenia studi improv
indirect glutam modul
depress psychosi subgroup patient psychosi comorbid
depress baselin studi engag sert
rel rare effect atyp antipsychot differenti
characterist abilifi aripiprazol drug approv
adjunct use depress even modest engag receptor
exhibit sert activ intra-cellular formal enter
phase bipolar depress expect program major depress
disord mdd follow
differenti profil may provid addit prosoci activ
molecul glutam major excitatori neurotransmitt brain
specif phosphoryl nmda receptor thought
enhanc glutam transmiss result agonist activ dopamin
receptor activ potenti provid addit efficaci
neg symptom schizophrenia social avoid flat affect etc
enhanc cognit set phase data
demonstr differenti respons compar risperd neg
symptom prosoci characterist characterist appear rare
atyp clozapin demonstr
enhanc activ signal exhibit
minim interact receptor associ metabol
littl activ receptor thought contribut weight
gain cognit dysfunct includ histamin receptor
muscarin cholinerg receptor addit lumateperon low affin
serotonin alpha adrenerg receptor minim activ
versu panel off-target system molecul lack activ
receptor born clinic studi shown littl glucos
weight gain lipid prolactin elev materi differenti compar
atyp olanzapin risperidon other demonstr
materi increas number metabol advers event
lumateperon region-specif brain activ demonstr
region-specif activ perhap underscor potenti efficaci
safeti antipsychot anim work shown
significantli increas extracellular dopamin concentr prefront
cortex striatum mesocortical-select increas
dopamin thought predictor antipsychot efficaci addit
lack disrupt striatal dopamin neurotransmiss also
predictor low potenti motor-rel side effect phase
pivot clinic work patient schizophrenia born potenti
demonstr uniqu aspect behavior
schizophrenia background schizophrenia chronic sever psychiatr
disord affect popul condit mental disord
character gross impair
percept realiti major
evidenc delus
hallucin incoher speech and/or disorgan agit behavior
reason often
schizophrenia associ substanti disabl primari goal
pharmacolog treatment reduc posit symptom relat
condit includ delus hallucin anoth goal therapi
reduc neg symptom apathi lack emot affect
lack interest social interact challeng goal includ
effect cognit symptom disord think reduc abil plan
execut task antipsychot gener materi effect posit
symptom modest effect neg symptom cognit
therapeut treatment schizophrenia materi challeng remain
signific proport patient approxim fail respond
treatment mani patient difficulti continu effect treatment
safeti toler issu discontinu rate
schizophrenia therapi high discontinu treatment within
month larg cati studi treatment also often involv
polypharmaci switch medicin due either lack efficaci advers
effect also quit common on-going medicin churn schizophrenia
patient believ creat opportun new differenti therapeut
success introduc patient
materi revenu opportun schizophrenia therapeut due
chronic use combin acut care price per day brand
schizophrenia categori even modestli success
therapeut reach sever hundr million dollar annual revenu
better behav molecul reach sever billion dollar revenu annual
peak seen multibillion-dollar success zyprexa olanzapin
compani rate risperd risperidon johnson johnson
review
atyp antipsychot case demonstr meaning efficaci
schizophrenia though also present challeng term safeti
toler leav plenti opportun novel molecul uniqu
pharmacolog profil includ efficaci compar
risperidon note phase along encouraging/mor
benefici effect prosoci factor well potenti antidepress
efficaci along appear rel benign effect metabol
condit low propens caus motoric/ep effect profil
appear one could consider appeal physician
revenu schizophrenia intra-cellular could signific
new drug applic nda file septemb final
us approv therapi gener schizophrenia
specif effect therapi modest differenti compar
exist standard potenti reach sever hundr million dollar
peak annual revenu atyp meaning benefit
compar exist therapi abl achiev peak revenu
excess billion indic consid believ
possess materi differenti follow uniqu pharmacolog
especi due rel benign advers event profil seen across
schizophrenia studi
lack
hyperprolactinemia weight gain associ metabol disturb
current estim abl reach billion peak global
revenu potenti indic assumpt revenu estim
includ net start price per day per patient maximum day
per patient therapi peak penetr approach
schizophrenia us schizophrenia diagnos
treat outer year come decad also includ revenu
long-act releas inject form consider
exhibit schizophrenia npv intra-cellular
level revenu combin probabl success given success
phase miss third larg trial assum tax rate
calcul fully-tax npv per share exhibit patent
expir therapi current extend molecul
composit though materi protect develop
believ could extend exclus us addit line
extens develop extend revenu
franchis model revenu base
molecul though note revenu franchis deriv part
long-act inject metabolit expect occur well past
market expens expect rather moder compar
us schizophrenia patient w/schiz us treat treat full day us revenu revenu us us revenu revenue us revenu us revenu lar version us label revenue- revenu partner cogs- cog royalti expense- d- sg us profit loss ict- eu/row licens partner up-front milestones- royalti royalty- total mileston royalty- total profit ict- eff tax tax- untaxed- npv/year taxed- total total valu value-per-share
launch though could exceed million
schizophrenia indic time
exhibit use beyond schizophrenia develop rational
regulatori fda health agenc oversight compani whose
main busi drug develop intra-cellular subject rigor
strenuou regulatori requir us food drug administr
fda intern medicin develop regulatori agenc
new drug approv market promot approv drug
product also regul fda relat agenc throughout globe
though compani specif focu ethic prescript pharmaceut
place signific risk oper believ risk time
greater less research-bas drug develop
compani biotechnology/biopharmaceut industri
materi depend upon success materi portion intra-
cellular estim revenu cash profit estim come
develop late stage cns-base therapi examin
schizophrenia sever cns-focus indic
demonstr signific clinic benefit efficaci safeti suffici satisfi
regulatori author fda emea larg anticip potenti
revenu cash profit expect result approv risk
could materi restrict compani sever way like materi
neg affect share note valuat comment
develop program materi investor interest believ
repres materi portion intra-cellular valuat therefor
progress progress effici along timelin anticip
materi risk share could trade neg result capit
loss sharehold
manufactur risk fda recent extrem increasingli vigil
inspect drug manufactur plant intra-cellular could subject
addit risk type fda regard manufactur iti-
submit licensur us approv
meaning problem intra-cellular manufactur oper
contract accomplish goal problem could
materi share
commerci risk particip market current larg
domin prescrib gener therapeut addit
consider commerci infrastructur necessari materi penetr
market antipsychot sold reason believ
import commerci adopt risk exist intra-cellular experi
market drug product current sale forc compani
unabl achiev signific product sale necessari profit
share could materi harm also intra-cellular fail obtain
intern commerci partner product share could also
reimburs risk patient physician insur may ascertain
benefit valu brand benefici light particular
insur could requir rigor requir prior author payment
prescript manag care significantli accept intra-
cellular product price indic product demand
could insuffici obtain profit sharehold
could experi neg return result
financi risk intra-cellular current approxim million cash
compani unabl obtain licensur us addit
intern market unabl suffici differenti compar
gener brand option indic pursu investor
percept share could substanti harm and/or materi
addit dilut exist sharehold possibl
risk model intra-cellular expect incur net loss
next year compani unabl predict extent futur loss
becom profit ever abl attain statu
manag certain member intra-cellular board director
benefici substanti amount equiti secur abl
exert substanti control organ intra-cellular therapi
emerg growth compani reduc disclosur requir
